One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Passage Bio logo
Passage Bio PASG
$ 3.36 -9.68%
report update icon

Quarterly report 2026-Q2
added 08-10-2026

Passage Bio Financial Ratios 2026-2011 | PASG

Annual Financial Ratios Passage Bio

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-2.5 -0.6 -0.0 -0.9 -0.5 -1.4 -4.0 - - - - - - - - -

EPS

-2.4 -14.3 -21.0 -1.9 -2.5 -3.5 -2.9 -10.8 - - - - - - - -

EV (Enterprise Value)

10.1 M 24 M 4.93 M 111 M 73.4 M 176 M 335 M -155 M 45.6 M - - - - - - -

EBITDA per Share

-2.53 -15.3 -21.9 -1.91 -2.48 -3.45 -4.68 - - - - - - - - -

EV/EBITDA

-1.2 -0.5 -0.1 -1.1 -0.5 -0.9 -2.8 - - - - - - - - -

PEG

-0.01 -0.0 - - - - 0.03 - - - - - - - - -

P/B

1.6 1.4 0.0 0.8 0.3 0.8 1.5 - - - - - - - - -

P/CF

-1.4 -0.9 -0.0 -1.2 -0.6 -2.1 -5.4 - - - - - - - - -

ROE %

-64.32 -245.27 -106.10 -91.71 -67.60 -58.18 -36.83 - - - - - - - - -

ROA %

-20.73 -73.86 -63.47 -67.80 -55.89 -52.21 -34.22 - - - - - - - - -

ROCE %

-70.18 -262.84 -114.92 -97.40 -68.73 -58.28 -36.80 - - - - - - - - -

Current Ratio

1.5 1.4 2.5 3.8 5.8 9.7 15.0 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Passage Bio

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-2.96 -2.36 - -2.44 -2.96 -0.25 - -6.15 -5.09 -0.3 - -0.49 -0.44 -0.63 - -0.49 -0.73 -0.79 - -0.87 -0.9 -0.76 - -0.63 -0.6 -1 - -2.68 -3.19 -1.83 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-3.2 -2.53 - -2.66 -3.2 -0.26 - -6.32 -5.28 -0.31 - -0.51 -0.45 -0.64 - -0.49 -0.72 -0.77 - -0.86 -0.9 -0.75 - -0.62 -0.6 -1.01 - -2.72 -1.83 -0.99 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-129.07 -146.74 -82.41 -109.01 -101.77 -93.17 -60.19 -81.66 -70.92 -73.42 -57.49 -69.39 -63.86 -63.22 -43.06 -56.01 -56.15 -49.02 -33.80 -43.16 -39.13 -32.86 -24.05 -3.81 29.42 51.97 57.74 20.24 23.87 13.63 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-58.10 -60.94 -40.21 -57.52 -59.82 -59.86 -41.95 -57.97 -52.98 -56.33 -44.44 -54.32 -51.15 -50.84 -34.74 -45.76 -35.87 -44.23 -31.38 -40.08 -36.36 -30.70 -22.34 -28.72 -27.54 -23.55 -18.19 -6.38 -7.52 -4.29 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-141.87 -160.24 -90.06 -118.53 -109.91 -100.11 -64.87 -87.58 -75.98 -77.86 -60.65 -72.92 -66.26 -64.60 -43.54 -56.54 -56.34 -49.11 -33.89 -43.28 -39.24 -33.05 -24.23 -3.54 19.67 36.07 41.95 20.70 13.81 7.44 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.4 1.5 2.5 1.7 1.9 2.2 2.5 2.9 3.6 3.9 3.8 3.9 4.5 5.0 5.8 5.9 - 6.4 9.8 13.6 11.8 19.6 14.1 14.1 14.1 14.1 41.9 41.9 41.9 41.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Passage Bio, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 3.23 -0.16 % $ 545 M singaporeSingapore
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.72 3.78 % $ 2.93 M usaUSA
XBiotech XBiotech
XBIT
$ 1.82 -5.7 % $ 55.5 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 35.76 1.19 % $ 2.83 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 10.21 0.05 % $ 1.64 B usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 3.26 0.46 % $ 138 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
22nd Century Group 22nd Century Group
XXII
$ 0.09 -54.43 % $ 16.6 K usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 24.36 1.35 % $ 26.7 B chinaChina
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 2.06 -6.79 % $ 148 M usaUSA
Zymeworks Zymeworks
ZYME
$ 28.38 0.57 % $ 1.46 B canadaCanada
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Otonomy Otonomy
OTIC
- -1.96 % $ 4.68 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Spectrum Pharmaceuticals Spectrum Pharmaceuticals
SPPI
- - $ 189 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.98 -2.78 % $ 247 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
VBI Vaccines VBI Vaccines
VBIV
- -50.87 % $ 1.09 M usaUSA
Certara Certara
CERT
$ 10.61 2.66 % $ 1.7 B usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA